Recent 8-K filings for CCEL

• May 8, 2026, 7:59 PM ET regulatory materiality 0.65 negative item 3.01item 7.01item 9.01 ◈ Listing & Compliance Notices

  NYSE American accepts Cryo-Cell compliance plan; trading continues through Sep 2027

  Received notice of non-compliance on Mar 12, 2026 for stockholders' deficit and net losses in two of three fiscal years ending Nov 30, 2025.

• March 12, 2026, 7:59 PM ET regulatory materiality 0.80 negative item 3.01item 7.01item 9.01 ◈ Listing & Compliance Notices

  Cryo-Cell receives NYSE American delisting notice over stockholders' deficit and net losses

  NYSE American cited stockholders' deficit as of Nov 30, 2025 and net losses in two of three fiscal years ended Nov 30, 2025.

• November 12, 2025, 6:59 PM ET dividend materiality 0.60 negative item 8.01

  Cryo-Cell International suspends Q4 2025 dividend; future payouts uncertain

  Company will not declare a quarterly cash dividend for Q4 fiscal 2025.

• May 22, 2025, 7:59 PM ET litigation materiality 0.85 negative item 1.02

  Duke terminates patent license with Cryo-Cell effective May 17; Cryo-Cell previously sought arbitration

  Duke University terminated Patent and Technology License Agreement effective May 17, 2025, claiming Cryo-Cell breached.

• May 8, 2025, 7:59 PM ET dividend materiality 0.60 negative item 8.01item 9.01

  Cryo-Cell reduces quarterly dividend to $0.15 per share, payable May 30, 2025

  Board declares reduced quarterly cash dividend of $0.15 per share, citing current economic environment and capital allocation alternatives.

• March 26, 2024, 7:59 PM ET other material materiality 0.60 neutral item 7.01item 9.01

  Cryo-Cell plans spin-off of Celle Corp. and explores strategic alternatives including sale

  Board authorized spin-off of newly formed Celle Corp. via stock dividend to Cryo-Cell shareholders.

• March 9, 2023, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements ×2

  Cryo-Cell amends Duke license, adds milestone for autism MSC therapy; funds IMPACT study

  Second Amendment removes final license fee payment to Duke; license fee now paid in full.

• February 24, 2022, 6:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Cryo-Cell reports FY2021 revenue $28.9M (-7% YoY), net income $2.1M (-42% YoY)

  Revenue $28.9M, down 7% from $31.1M; processing/storage fees $28.4M vs $29.5M.

• July 19, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Cryo-Cell Q2 fiscal 2021 revenue down 8% to $7.21M; net income rises to $1.17M

  Revenue $7.21M, down 8% from $7.87M; processing/storage fees $7.16M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.50 · Most common event other

3 positive 7 negative 19 neutral

source · CCEL on sec.gov